EUVIMEDEUVIMED entdecken
Crossref

1753-P: CGM-Based Metrics in Insulin-Naive Adults with T2D Receiving IcoSema vs. Glargine U100: Post Hoc Analysis of COMBINE 4.

CONCETTA IRACE, RALUCA MALTESEN, LAURA PLETSCH BORBA, THAIS M. PAGLIARO ROCHA, YASUO TERAUCHI, CHANTAL MATHIEU

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1753-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von CONCETTA IRACE und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: IcoSema is a once-weekly combination therapy of insulin icodec + semaglutide. This post hoc analysis assessed CGM-based metrics of IcoSema vs glargine U100 using blinded CGM data from COMBINE 4, a 40-week, phase 3b trial in T2D.

Methods

Adults with T2D inadequately controlled on oral glucose-lowering medications were randomized 1:1 to IcoSema or glargine U100. Time in tight range (TITR, 70-140 mg/dL); achievement of the double composite CGM target (>70% time in range [70-180mg/dL] + <4% time <70 mg/dL); coefficient of variation (CV%); and duration of CGM-based overall hypoglycemic episodes (<70 mg/dL for >=15 consecutive min) were assessed during weeks 36-40.

Results

Mean percentage of TITR was statistically significantly higher with IcoSema vs glargine U100 (p<0.0001; Table). Odds of achieving the double composite CGM target were statistically significantly higher with IcoSema vs glargine U100 (p=0.0004). Geometric mean CV% was <36% in both groups, with a numerically higher proportion of participants achieving CV% <36% with IcoSema vs glargine U100. Median duration of overall hypoglycemic episodes was comparable between groups.

Conclusion

Compared with glargine U100, IcoSema was associated with improved glycemic control. These findings support IcoSema as a potential once-weekly alternative to daily basal insulin for treatment intensification in insulin-naive adults with T2D. Disclosure C. Irace: Board Member; Ended; Abbott Diabetes. Board Member; Current; Novo Nordisk. Speaker's Bureau; Ended; Medtronic. Board Member; Current; Roche Diabetes Care. Speaker's Bureau; Ended; Novo Nordisk, Lilly. R. Maltesen: Employee; Current; Novo Nordisk. L. Pletsch Borba: Employee; Current; Novo Nordisk A/S. Stock/Shareholder; Current; Novo Nordisk A/S. T.M. Pagliaro Rocha: None. Y. Terauchi: Speaker's Bureau; Current; Astellas Pharma Inc., AstraZeneca, Eli Lilly and Company, Kowa Company, Ltd., Mitsubishi Tanabe Pharma Corporation, Merck Sharp & Dohme Corp., Nippon Boehringer Ingelheim Co. Ltd., Novo Nordisk, Sanofi, Sumitomo Pharma. Research Support; Current; Eli Lilly and Company, Nippon Boehringer Ingelheim Co. Ltd., Sumitomo Pharma. C. Mathieu: Advisory Panel; Current; Abbott Diagnostics, Dexcom, Inc. Board Member; Current; European Association for the Study of Diabetes. Advisory Panel; Current; Novo Nordisk, Eli Lilly and Company, Sanofi, Vertex Pharmaceuticals Incorporated, Medtronic. Funding Supported by Novo Nordisk A/S

Zitieren

APA

IRACE, C., MALTESEN, R., BORBA, L. P., ROCHA, T. M. P., TERAUCHI, Y., & MATHIEU, C. (2026). 1753-P: CGM-Based Metrics in Insulin-Naive Adults with T2D Receiving IcoSema vs. Glargine U100: Post Hoc Analysis of COMBINE 4. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1753-p

Vancouver

IRACE C, MALTESEN R, BORBA LP, ROCHA TMP, TERAUCHI Y, MATHIEU C. 1753-P: CGM-Based Metrics in Insulin-Naive Adults with T2D Receiving IcoSema vs. Glargine U100: Post Hoc Analysis of COMBINE 4. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1753-p

BibTeX
@article{IRACE2026,
  author = {IRACE, CONCETTA and MALTESEN, RALUCA and BORBA, LAURA PLETSCH and ROCHA, THAIS M. PAGLIARO and TERAUCHI, YASUO and MATHIEU, CHANTAL},
  title = {1753-P: CGM-Based Metrics in Insulin-Naive Adults with T2D Receiving IcoSema vs. Glargine U100: Post Hoc Analysis of COMBINE 4},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1753-p}
}
Kostenlos starten →